# US 2010/0168214 A1 · Nucleic acid and corresponding protein entitled 151p3d4 useful in treatment and detection of cancer > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2010/0168214 A1 - Document ID: US20100168214A1 - Status: Published application - Kind: A1 - Application number: 12/687,768 - Filed: 2010-01-14 - Published: 2010-07-01 - Earliest claimed: 2001-04-10 - Assignees: Agensys, Inc. - Inventors: Pia M. Challita-Eid; Arthur B. Raitano; Mary Faris; Rene S. Hubert; Karen Jane Meyrick Morrison; Robert Kendall Morrison; Wangmao Ge; Aya Jakobovits - Web page: https://patentgrep.com/patent/US20100168214A1 ## CPC - C07K 14/47: from mammals - A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics - A61P 35/00: Antineoplastic agents - C12N 9/78: acting on carbon to nitrogen bonds other than peptide bonds (3.5) - A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) - Y10T 436/25: including sample preparation - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION ## Abstract A novel gene (designated 151P3D4) and its encoded protein, and variants thereof, are described wherein 151P3D4 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 151P3D4 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 151P3D4 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 151P3D4 can be used in active or passive immunization. ## Claims ### Claim 1 An isolated polynucleotide, comprising the nucleotide sequence of SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20 or SEQ ID NO: 22. ### Claim 2 (depends on 1) The isolated polynucleotide of claim 1, the nucleotide sequence of which is selected from the group consisting of SEQ ID NOs: 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22. ### Claim 3 (depends on 1) A pharmaceutical composition, comprising the isolated polynucleotide of claim 1 and a pharmaceutically acceptable carrier. ### Claim 4 (depends on 1) A recombinant viral expression vector, comprising the isolated polynucleotide of claim 1. ### Claim 5 (depends on 4) The recombinant viral expression vector of claim 4, wherein the viral expression vector is selected from the group consisting of vaccinia, fowlpox, canarypox, adenovirus, influenza, poliovirus, adeno-associated virus, lentivirus, and Sindbis virus vectors. ### Claim 6 (depends on 5) An isolated host cell that contains the expression vector of claim 5. ### Claim 7 (depends on 6) A process for producing a protein, comprising: culturing the isolated host cell of claim 6 under conditions sufficient for the production of a protein from the expression vector, and recovering the protein from the culture. ### Claim 8 (depends on 8) The process of claim 8, wherein the protein is recovered using chromatography. ### Claim 9 An isolated polynucleotide, comprising: (a) the sequence of SEQ ID NO:4, from nucleotide residue numbers 1 through 2166; (b) the sequence of SEQ ID NO:12, from nucleotide residue numbers 316 through 1380; or (c) the sequence of SEQ ID NO:14, from nucleotide residue numbers 316 through 1380. ### Claim 10 (depends on 9) A pharmaceutical composition, comprising the isolated polynucleotide of claim 9 and a pharmaceutically acceptable carrier. ### Claim 11 (depends on 9) A recombinant expression vector, comprising the isolated polynucleotide of claim 9, wherein the vector is a viral vector. ### Claim 12 (depends on 11) The recombinant expression vector of claim 11, wherein the viral vector is selected from the group consisting of vaccinia, fowlpox, canarypox, adenovirus, influenza, poliovirus, adeno-associated virus, lentivirus, and Sindbis virus. ### Claim 13 (depends on 12) An isolated host cell that contains the expression vector of claim 12. ### Claim 14 (depends on 13) A process for producing a protein, comprising: culturing the isolated host cell of claim 13 under conditions sufficient for the production of a protein from the expression vector, and recovering the protein from the culture. ### Claim 15 (depends on 14) The process of claim 14, wherein the protein is recovered using chromatography.